Tevogen Inc.
TVGNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tevogen Inc. focuses on Biotechnology services and products. Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company carries a $102.8M market cap, placing it firmly in the micro-cap category. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Market Cap
$102.8M
Beta
0.20
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-6.74
EPS (Fwd)
—
ROE
—
ROA
-297.4%
Cash
$1.1M
Total Debt
$9.4M
Free CF
-$3.1M
52W Change
-80.4%
Annual Financials
Cash vs Debt
Where TVGN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TVGN finished 3.01% below its 150-day moving average ($6.98) and 22.18% below its 200-day moving average ($8.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TVGN overbought or oversold?
At the October 20, 2026 close, TVGN's RSI(14) was 50.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, TVGN has $1.1M in cash with $9.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$3.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
TVGN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Tevogen Inc. and its sector.